Cipher Research And Ddevelopement To Revenue from 2010 to 2024
| CPH Stock | CAD 14.40 0.16 1.12% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 0.02079199 | Current Value 0.0198 | Quarterly Volatility 0.17752286 |
Check Cipher Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cipher Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 506.9 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0458 or PTB Ratio of 1.26. Cipher financial statements analysis is a perfect complement when working with Cipher Pharmaceuticals Valuation or Volatility modules.
Cipher | Research And Ddevelopement To Revenue |
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cipher Stock
| 0.78 | AMZN | Amazon CDR | PairCorr |
| 0.67 | BNS | Bank of Nova Scotia Earnings Call This Week | PairCorr |
| 0.65 | BMO | Bank of Montreal | PairCorr |
| 0.45 | RY | Royal Bank Earnings Call This Week | PairCorr |
| 0.41 | TD-PFI | Toronto Dominion Bank | PairCorr |
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.